ATYR PHARMA INC (ATYR)
US0021202025 - Common Stock
ATYR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 573 industry peers in the Biotechnology industry. While ATYR seems to be doing ok healthwise, there are quite some concerns on its profitability. ATYR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
ATYR had negative earnings in the past year.
ATYR had a negative operating cash flow in the past year.
ATYR had negative earnings in each of the past 5 years.
In the past 5 years ATYR always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -54.65%, ATYR is in line with its industry, outperforming 43.66% of the companies in the same industry.
Looking at the Return On Equity, with a value of -70.95%, ATYR is in line with its industry, outperforming 56.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -54.65% | ||
| ROE | -70.95% | ||
| ROIC | N/A |
ROA(3y)-39.44%
ROA(5y)-45.09%
ROE(3y)-49.97%
ROE(5y)-62.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ATYR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
ATYR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ATYR has been increased compared to 5 years ago.
Compared to 1 year ago, ATYR has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -4.11, we must say that ATYR is in the distress zone and has some risk of bankruptcy.
ATYR has a Altman-Z score of -4.11. This is comparable to the rest of the industry: ATYR outperforms 41.20% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ATYR is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, ATYR is in line with its industry, outperforming 45.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.11 |
ROIC/WACCN/A
WACC10.25%
2.3 Liquidity
ATYR has a Current Ratio of 7.63. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
ATYR has a better Current ratio (7.63) than 70.95% of its industry peers.
A Quick Ratio of 7.63 indicates that ATYR has no problem at all paying its short term obligations.
The Quick ratio of ATYR (7.63) is better than 70.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.63 | ||
| Quick Ratio | 7.63 |
3. Growth
3.1 Past
ATYR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.02%, which is quite impressive.
The Revenue for ATYR has decreased by -94.34% in the past year. This is quite bad
Measured over the past years, ATYR shows a very negative growth in Revenue. The Revenue has been decreasing by -67.68% on average per year.
EPS 1Y (TTM)26.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.55%
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 37.60% on average over the next years. This is a very strong growth
Based on estimates for the next years, ATYR will show a very strong growth in Revenue. The Revenue will grow by 301.41% on average per year.
EPS Next Y2.46%
EPS Next 2Y6.34%
EPS Next 3Y23.81%
EPS Next 5Y37.6%
Revenue Next Year-30.06%
Revenue Next 2Y288.48%
Revenue Next 3Y448.92%
Revenue Next 5Y301.41%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ATYR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATYR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ATYR's earnings are expected to grow with 23.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.34%
EPS Next 3Y23.81%
5. Dividend
5.1 Amount
ATYR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ATYR PHARMA INC
NASDAQ:ATYR (9/16/2024, 3:09:48 PM)
1.93
+0.03 (+1.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap146.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -54.65% | ||
| ROE | -70.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.63 | ||
| Quick Ratio | 7.63 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)26.02%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y2.46%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-94.34%
Revenue growth 3Y-67.68%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y